157 related articles for article (PubMed ID: 16820545)
1. NMP22 and surveillance for recurrent bladder cancer.
Eggener S; Herr H
JAMA; 2006 Jul; 296(1):45; author reply 45-6. PubMed ID: 16820545
[No Abstract] [Full Text] [Related]
2. NMP22 and surveillance for recurrent bladder cancer.
Wilson CT
JAMA; 2006 Jul; 296(1):44-5; author reply 45-6. PubMed ID: 16820544
[No Abstract] [Full Text] [Related]
3. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
[TBL] [Abstract][Full Text] [Related]
4. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
[TBL] [Abstract][Full Text] [Related]
5. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer.
Witjes JA; van der Poel HG; van Balken MR; Debruyne FM; Schalken JA
Eur Urol; 1998; 33(4):387-91. PubMed ID: 9612682
[TBL] [Abstract][Full Text] [Related]
6. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
Serretta V; Pomara G; Rizzo I; Esposito E
Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
[TBL] [Abstract][Full Text] [Related]
7. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder.
Shelfo SW; Soloway MS
World J Urol; 1997; 15(2):107-11. PubMed ID: 9144900
[TBL] [Abstract][Full Text] [Related]
8. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
[TBL] [Abstract][Full Text] [Related]
9. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
10. Detection of recurrent bladder cancer: NMP22 test or urine cytology?
Hosseini J; Golshan AR; Mazloomfard MM; Mehrsai AR; Zargar MA; Ayati M; Shakeri S; Jasemi M; Kabiri M
Urol J; 2012; 9(1):367-72. PubMed ID: 22395834
[TBL] [Abstract][Full Text] [Related]
11. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.
Chou R; Gore JL; Buckley D; Fu R; Gustafson K; Griffin JC; Grusing S; Selph S
Ann Intern Med; 2015 Dec; 163(12):922-31. PubMed ID: 26501851
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic significance of protein NMP22 in bladder cancer].
Rybotycka Z; Długosz A
Pol Merkur Lekarski; 2015 Jun; 38(228):309-14. PubMed ID: 26098648
[TBL] [Abstract][Full Text] [Related]
13. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.
Shariat SF; Savage C; Chromecki TF; Sun M; Scherr DS; Lee RK; Lughezzani G; Remzi M; Marberger MJ; Karakiewicz PI; Vickers AJ
Cancer; 2011 Jul; 117(13):2892-7. PubMed ID: 21692050
[TBL] [Abstract][Full Text] [Related]
14. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
17. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
18. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
19. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
20. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]